Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. cut its position in shares of Scholar Rock Holding Co. (NASDAQ:SRRK) by 57.6% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 20,600 shares of the company’s stock after selling 28,000 shares during the quarter. Polar Asset Management Partners Inc.’s holdings in Scholar Rock were worth $890,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of SRRK. Vanguard Group Inc. grew its stake in Scholar Rock by 17.6% in the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company’s stock worth $205,013,000 after acquiring an additional 708,817 shares during the period. Principal Financial Group Inc. acquired a new position in Scholar Rock in the fourth quarter valued at $274,000. Blackstone Inc. purchased a new position in Scholar Rock during the fourth quarter worth about $910,000. Rhumbline Advisers lifted its holdings in shares of Scholar Rock by 13.2% during the 4th quarter. Rhumbline Advisers now owns 113,261 shares of the company’s stock worth $4,895,000 after acquiring an additional 13,247 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Scholar Rock in the fourth quarter valued at approximately $2,625,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Stock Performance

Scholar Rock stock opened at $30.55 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98. The stock’s 50-day moving average is $31.19 and its 200-day moving average is $35.91. The company has a market cap of $2.90 billion, a price-to-earnings ratio of -13.00 and a beta of 0.37.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.04). Equities analysts anticipate that Scholar Rock Holding Co. will post -2.42 earnings per share for the current year.

Insider Activity

In other Scholar Rock news, insider Tracey Sacco sold 6,500 shares of the company’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $33.08, for a total value of $215,020.00. Following the completion of the transaction, the insider now directly owns 71,750 shares of the company’s stock, valued at $2,373,490. This represents a 8.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Edward H. Myles sold 142,292 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $35.62, for a total value of $5,068,441.04. Following the sale, the chief financial officer now owns 111,345 shares of the company’s stock, valued at $3,966,108.90. This represents a 56.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 255,231 shares of company stock worth $9,220,236 over the last 90 days. Company insiders own 13.30% of the company’s stock.

Analyst Ratings Changes

Separately, Wedbush reaffirmed an “outperform” rating and set a $50.00 price target on shares of Scholar Rock in a research note on Wednesday. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Scholar Rock currently has an average rating of “Buy” and an average target price of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.